---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-011680"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2022-03-24T23:59:59+00:00"
generated_at: "2026-06-26T18:16:46.133494+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Eledon Pharma reports FY2021 net loss of $34.5M; cash $84.8M into 2024

## Summary
- Net loss for Q4 2021 was $8.8M ($0.59/share); FY2021 net loss $34.5M ($2.33/share).
- R&D expense rose to $23.7M in FY2021 from $6.1M in FY2020, driven by tegoprubart trials.
- Cash and equivalents $84.8M at Dec 31, 2021, down from $114.2M a year earlier.
- Topline Phase 2a tegoprubart data in ALS expected in Q2 2022; kidney, IgAN, islet data in Q4 2022.
- No revenue recorded; net loss widened due to increased clinical development costs.

## SEC filing metadata
- accession: 0001564590-22-011680
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2022-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000156459022011680/0001564590-22-011680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000156459022011680/eldn-8k_20220324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-011680
- JSON: https://secwatch.observer/filing/0001564590-22-011680.json
- Plain text: https://secwatch.observer/filing/0001564590-22-011680.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.